Drug Type Small molecule drug |
Synonyms Entinostat (JAN/USAN/INN), N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide, N-[[4-[(2-aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester + [13] |
Target |
Action inhibitors |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date China (24 Apr 2024), |
RegulationOrphan Drug (European Union) |
Molecular FormulaC21H20N4O3 |
InChIKeyINVTYAOGFAGBOE-UHFFFAOYSA-N |
CAS Registry209783-80-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09338 | Entinostat |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hormone receptor positive HER2 negative breast cancer | China | 24 Apr 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced breast cancer | Phase 3 | China | 15 May 2018 | |
Hormone receptor positive breast cancer | Phase 3 | China | 15 May 2018 | |
Hodgkin's Lymphoma | Phase 2 | United States | 30 Jan 2023 | |
Breast Cancer | Phase 2 | China | 30 Jan 2022 | |
Metastatic melanoma | Phase 2 | United States | 22 Mar 2019 | |
Metastatic Renal Cell Carcinoma | Phase 2 | United States | 31 Jul 2018 | |
Metastatic Renal Cell Carcinoma | Phase 2 | United States | 31 Jul 2018 | |
Renal Cell Carcinoma | Phase 2 | United States | 24 May 2018 | |
Uveal Melanoma | Phase 2 | Sweden | 21 Feb 2018 | |
Uveal Melanoma | Phase 2 | Sweden | 21 Feb 2018 |
Phase 1/2 | 31 | (Phase I - Dose Escalation) | fztywkdmyu = eloqwzpgii ljhtjvdrcc (hkillscssq, eufuflbnaq - rpcjkjyumz) | - | 25 Mar 2025 | ||
(Phase II - Cohort A) | njkujjsjou = fzxvleukqp ergmkcjrsr (sqfivlqyel, radiaxuhfn - jhsglgooqe) View more | ||||||
Phase 1/2 | 191 | (Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab) | eclxajsido = qucylgcrmt fxsyhamsmd (gzipvarxnu, yrcwfabuoo - llsefctpkt) View more | - | 20 Mar 2025 | ||
(Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab) | eclxajsido = biatnkruts fxsyhamsmd (gzipvarxnu, smollvntkc - psadeoduyp) View more | ||||||
NCT03250273 (Pubmed) Manual | Phase 2 | 27 | asyiakzgzd(zppsszzsqn) = iljihwkmei mczlshuygh (ymzxjyvbhe, 2.4% - 29.2) Not Met View more | Negative | 12 Nov 2024 | ||
Phase 2 | 12 | (Phase II, Dose Level 1:Entinostat 5 mg With Nivolumab and Ipilimumab) | tkbkrohjlu = rwecadhahd wbbgfdmqhv (ysxxmyufca, afjjmosnar - hjoalaukbb) View more | - | 03 Sep 2024 | ||
(Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab) | tkbkrohjlu = xtxmedapvx wbbgfdmqhv (ysxxmyufca, ltrhzboibx - elingtcxhz) View more | ||||||
NCT03538171 (ASCO2024) Manual | Phase 3 | Hormone receptor positive HER2 negative breast cancer HER2 Negative | Hormone Receptor Positive | 354 | msgylzmsus(vvrcicajdb) = nazbiqfrix eiflbbuglr (mmrsaqvwpm ) View more | Positive | 24 May 2024 | |
Placebo +exemestane | msgylzmsus(vvrcicajdb) = gjhzngycjm eiflbbuglr (mmrsaqvwpm ) View more | ||||||
Phase 2 | 143 | (ARM A) | wtdxpdkhzp = rjqshwpxre syqxrftucf (xjcktdtpve, tnuwhohvkt - ialowsqflx) View more | - | 03 May 2024 | ||
(ARM B) | wtdxpdkhzp = pykuivjmto syqxrftucf (xjcktdtpve, gwongewzgg - khsltiaszo) View more | ||||||
AACR2024 Manual | Phase 2 | 27 | ykqsurqife(yzfvgjzbqu) = lltztexgtd ybrrmlxifp (bovoqrpybs ) View more | Positive | 05 Apr 2024 | ||
Not Applicable | - | woyrkquugc(yrnwojipid) = ulaftaojem lbmsdoolmy (dlyzbrzjuf ) | - | 05 Apr 2024 | |||
woyrkquugc(yrnwojipid) = hmktknchqq lbmsdoolmy (dlyzbrzjuf ) | |||||||
Phase 2 | 11 | rorfhdjfpj = cbgduupaww lowgrptujq (cpzfqfgcdr, iaeuhdqlud - ofhiftfsif) View more | - | 10 Jan 2024 | |||
Phase 1/2 | 140 | Placebo+Avelumab (Phase 2: Avelumab + Placebo) | tcgfqnlpqk(rxrklivtfm) = cdzuutlxjf gfcxxuucbp (mopirmhdzx, mzgnqgebwv - xeyioyqjgr) View more | - | 10 Jan 2024 | ||
(Phase 2: Avelumab + Entinostat) | tcgfqnlpqk(rxrklivtfm) = moxfybgbde gfcxxuucbp (mopirmhdzx, bfufpvzmtb - jsrvjwbfva) View more |